



NDA 008943/S-053

NDA 009388/S-039

SUPPLEMENT APPROVAL

Teva Branded Pharmaceutical Products R&D, Inc.
Attention: Danielle Moffett, PhD
Associate Director, Regulatory Affairs
145 Brandywine Parkway
West Chester, PA 19380

Dear Dr. Moffett:

Please refer to your supplemental new drug applications (sNDAs) dated and received May 22, 2024, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for DIAMOX (acetazolamide, USP) tablets, 125 mg and 250 mg, and DIAMOX (acetazolamide for injection, USP). These Prior Approval sNDAs provide for the addition of “choroidal effusion” and “choroidal detachment” in the ADVERSE REACTIONS and PRECAUTIONS sections of the Prescribing Information.

APPROVAL & LABELING

We have completed our review of these applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling with minor editorial revisions reflected in the enclosed labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.¹ Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information), with the addition of any labeling changes in pending “Changes Being Effectuated” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.²

The SPL will be accessible from publicly available labeling repositories.

¹ <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

PATENT LISTING REQUIREMENTS

Pursuant to 21 CFR 314.53(d)(2) and 314.70(f), certain changes to an approved NDA submitted in a supplement require you to submit patent information for listing in the Orange Book upon approval of the supplement. You must submit the patent information required by 21 CFR 314.53(d)(2)(i)(A) through (C) and 314.53(d)(2)(ii)(A) and (C), as applicable, to FDA on Form FDA 3542 within 30 days after the date of approval of the supplement for the patent information to be timely filed (see 21 CFR 314.53(c)(2)(ii)). You also must ensure that any changes to your approved NDA that require the submission of a request to remove patent information from the Orange Book are submitted to FDA at the time of approval of the supplement pursuant to 21 CFR 314.53(d)(2)(ii)(B) and 314.53(f)(2)(iv).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions regarding NDA 008943, contact Dheera Semidey, Senior Regulatory Project Manager, at (301) 796-3009 or dheera.semidey@fda.hhs.gov.

If you have any questions regarding NDA 009388, contact Jacquelyn Smith, Senior Regulatory Project Manager, at (301) 796-1002 or jacquelyn.smith@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

William Boyd, MD
Deputy Director
Division of Ophthalmology
Office of Specialty Medicine
Office of New Drugs
Center for Drug Evaluation and Research

ENCLOSURE:

- Content of Labeling
 - o Prescribing Information

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

WILLIAM M BOYD
09/20/2024 11:44:32 AM